Last Updated : April 13, 2023
The objective of the drug utilization study is to determine real-world omalizumab use patterns in patients with chronic idiopathic urticaria (CIU). The focus is on identifying the incidence and prevalence of use beyond 24 weeks.
A companion systematic review (RE0043) will determine the efficacy, effectiveness, and safety of omalizumab administered for 24 weeks or longer in patients with CIU. The review will also identify the characteristics of patients who use omalizumab for longer than 24 weeks.
Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.
The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.